Adherence, Acceptability and Tolerability of Venlafaxine Extended Release at Dose of 300 Mg/day in Patients with Major Depressive Disorder

Overview

Journal Actas Esp Psiquiatr

Specialty Psychiatry

Date 2023 Dec 20

PMID 38117259

Authors

Ignacio Gainza-Tejedor

Pablo L Moreno-Flores

Froilan Mendez-Cordovez

Celia Sanchez-Gravie

Cagla Defterali

Pedro Sanchez-Gomez

Affiliations

Soon will be listed here.

Abstract

Adherence to antidepressants is essential for good outcomes when treating depressive disorders.

Citing Articles

Osteoporosis and Fracture Risk Associated with Novel Antidepressants: A Systematic Review and Meta-Analysis.

Hu J, Xie K, Wu S, Chen Y Actas Esp Psiquiatr. 2024; 52(3):334-346.

PMID: 38863057 PMC: 11190450. DOI: 10.62641/aep.v52i3.1560.

References

Lieberman D, Montgomery S, Tourian K, Brisard C, Rosas G, Padmanabhan K . A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008; 23(4):188-97. DOI: 10.1097/YIC.0b013e32830263de. View

Kienke A, Rosenbaum J . Efficacy of venlafaxine in the treatment of severe depression. Depress Anxiety. 2000; 12 Suppl 1:50-4. DOI: 10.1002/1520-6394(2000)12:1+<50::AID-DA6>3.0.CO;2-4. View

Rickels K, Gallop R, Cleary S . The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder. J Clin Psychopharmacol. 2019; 39(3):258-260. DOI: 10.1097/JCP.0000000000001027. View

Kores Plesnicar B . Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder. Psychiatr Danub. 2010; 22(3):413-7. View

Atkinson M, Sinha A, Hass S, Colman S, Kumar R, Brod M . Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004; 2:12. PMC: 398419. DOI: 10.1186/1477-7525-2-12. View

Stahl S, Entsuah R, Rudolph R . Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry. 2002; 52(12):1166-74. DOI: 10.1016/s0006-3223(02)01425-7. View

George C, Peveler R, Heiliger S, Thompson C . Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Pharmacol. 2000; 50(2):166-71. PMC: 2014396. DOI: 10.1046/j.1365-2125.2000.00244.x. View

Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P . Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2006; 10(1):51-61. DOI: 10.1017/S1461145705006413. View

Diez-Quevedo C, Rangil T, Sanchez-Planell L, Kroenke K, Spitzer R . Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients. Psychosom Med. 2001; 63(4):679-86. DOI: 10.1097/00006842-200107000-00021. View

10.

Marwaha S, Palmer E, Suppes T, Cons E, Young A, Upthegrove R . Novel and emerging treatments for major depression. Lancet. 2022; 401(10371):141-153. DOI: 10.1016/S0140-6736(22)02080-3. View

11.

Solmi M, Miola A, Croatto G, Pigato G, Favaro A, Fornaro M . How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Braz J Psychiatry. 2020; 43(2):189-202. PMC: 8023158. DOI: 10.1590/1516-4446-2020-0935. View

12.

Nemeroff C, Entsuah R, Benattia I, Demitrack M, Sloan D, Thase M . Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2007; 63(4):424-34. DOI: 10.1016/j.biopsych.2007.06.027. View

13.

Ruiz-Doblado S, Rueda-Villar T, Casillas-Lara L . High-dose venlafaxine in delusional and severely depressed patients. J Psychopharmacol. 2008; 23(7):859-60. DOI: 10.1177/0269881108091589. View

14.

Vermeire E, Hearnshaw H, Van Royen P, Denekens J . Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001; 26(5):331-42. DOI: 10.1046/j.1365-2710.2001.00363.x. View

15.

Lopez-Torres J, Parraga I, Del Campo J, Villena A . Follow up of patients who start treatment with antidepressants: treatment satisfaction, treatment compliance, efficacy and safety. BMC Psychiatry. 2013; 13:65. PMC: 3599847. DOI: 10.1186/1471-244X-13-65. View

16.

Malhi G, Mann J . Depression. Lancet. 2018; 392(10161):2299-2312. DOI: 10.1016/S0140-6736(18)31948-2. View

17.

Val Jimenez A, Amoros Ballestero G, Martinez Visa P, Fernandez Ferre M, Leon Sanroma M . [Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test]. Aten Primaria. 1992; 10(5):767-70. View

18.

Adli M, Baethge C, Heinz A, Langlitz N, Bauer M . Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2005; 255(6):387-400. DOI: 10.1007/s00406-005-0579-5. View

19.

Thase M, Shelton R, Khan A . Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol. 2006; 26(3):250-8. DOI: 10.1097/01.jcp.0000219922.19305.08. View

20.

Badia X . [Satisfaction with treatment]. Med Clin (Barc). 2005; 125(3):98-9. DOI: 10.1157/13076936. View